Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28993722 | 0.83 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL27509183 | 0.81 | TSHR (0.57) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL666545 | 0.81 | TSHR (0.57) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL901056 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL58206 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL25293204 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL2856970 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL2068701 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| SCHEMBL5954673 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB | |
| Benzene SCHEMBL25178056 | 0.77 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102762564-B | Georelin receptor agonists for the treatment of cachexia | RAQUALIA PHARMA INC. (JP) | 2015-09-30 | — | — | CN | disclosed |
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2805948-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | Santen Pharmaceutical Co., Ltd (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-104136432-A | Industrial process for producing 1, 2-dihydroquinoline derivative or salt thereof and intermediate for producing the same | SANTEN PHARMACEUTICAL CO LTD | 2014-11-05 | — | — | CN | disclosed |
| CN-101600700-B | Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | disclosed |
| CN-102378751-A | Improved process for preparing dipeptidyl peptidase-IV inhibitors and intermediates | DONG A PHARM CO LTD | 2012-03-14 | — | — | CN | disclosed |
| EP-1106610-B1 | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1019395-B1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-30 | — | — | EP | disclosed |
| EP-1106610-A1 | Farnesyl transferase inhibiting 2-quinolone derivatives | Janssen Pharmaceutica N.V. (BE) | 2001-06-13 | — | — | EP | disclosed |
| EP-1019395-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | disclosed |
| US-5968952-A | ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-10-19 | — | — | US | disclosed |
| WO-1997016443-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | NR3C2, NR5A1, NR3C1 | TSHR 555/4885IDO1 2632/4885AGXT 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.